Showing results (11-20 of 56) with videos related to
Sort By:
Pageof 6
Biochemical Pharmacology|March 16, 2000
Isolation and characterization of a cDNA encoding a horse liver butyrylcholinesterase: evidence for CPT-11 drug activationM Wierdl, C L Morton, M K Danks, et al.Cancer Research|September 15, 2000
Proficient metabolism of irinotecan by a human intestinal carboxylesteraseR Khanna, C L Morton, M K Danks, et al.Cancer Research|August 1, 1992
DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitorsJ S Wolverton, M K Danks, B Granzen, et al.Cancer Research|April 1, 1996
Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecanM K Danks, K E Garrett, R C Marion, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposureM K Danks, C A Pawlik, D O Whipple, et al.Proceedings of the National Academy of Sciences of the United States of America|September 1, 1991
Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposideB Y Bugg, M K Danks, W T Beck, et al.Cancer Communications|January 1, 1989
Increased ATP requirement for activity of and complex formation by DNA topoisomerase II from human leukemic CCRF-CEM cells selected for resistance to teniposideM K Danks, C A Schmidt, D A Deneka, et al.Cancer Research|January 13, 1998
Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11M K Danks, C L Morton, C A Pawlik, et al.Cancer Research|May 1, 1989
Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cellsJ S Wolverton, M K Danks, C A Schmidt, et al.Cancer Research|July 1, 1985
Monoclonal antibodies to glycoproteins of Vinca alkaloid-resistant human leukemic cellsM K Danks, D W Metzger, R A Ashmun, et al.Pageof 6